MedPath

Dose-response of Cannabis and Driving

Phase 2
Completed
Conditions
Driving Impaired
Abuse Cannabis
Cognitive Impairment
Interventions
Drug: Placebo
Registration Number
NCT03656029
Lead Sponsor
Centre for Addiction and Mental Health
Brief Summary

Epidemiological studies have established a link between collisions while driving and cannabis use. With the changing legal landscape around cannabis, there is much interest in determining per se limits of cannabis while driving. The present study will evaluate driving on a driving simulator after smoking placebo or cannabis with 3 different levels of THC. THC is the active component in cannabis and blood, urine and oral fluid levels of THC will be correlated with driving impairment.

Detailed Description

Participants will attend the laboratory for 4 separate sessions, separated by about a week. In each session, participants will receive one of 3 doses of smoked cannabis or a placebo. Participants will not know which dose they are receiving. Participants will complete questionnaires, do cognitive tests and drive on a driving simulator before and after smoking the cannabis or placebo cigarette. Blood, urine and oral fluid will be collected throughout the 7-8 hour session to determine levels of THC and its metabolites. These values will be correlated with measures of driving impairment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Near daily use of cannabis (1-5 days/week) confirmed by self-report and urine screening
  • Has held a class G2 or G licence (or equivalent from another jurisdiction) for at least 12 months
  • Willing to abstain from using cannabis for 72 hours prior to each practice or test session
  • Willing to abstain from alcohol for 48 hours prior to each session, and to abstain from all other drugs not medically required for the duration of the study (beginning 48 hours prior to the practice session)
  • Provides written and informed consent
Exclusion Criteria
  • Diagnosis of severe medical or psychiatric condition
  • Meets criteria for current or lifetime alcohol or other substance use disorder, except tobacco use disorder and caffeine use disorder
  • Regular user of medication that may affect cognitive functioning and/or driver performance
  • Family history of schizophrenia or other psychotic disorder
  • Pregnant, looking to become pregnant, or breastfeeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboParticipants will smoke a single smoked placebo (\<0.1% THC) cannabis cigarette
low doseCannabisParticipants will smoke a single low dose (6.25% THC) of smoked cannabis cigarette
middle doseCannabisParticipants will smoke a single intermediate dose (12.5% THC) of smoked cannabis cigarette
high doseCannabisParticipants will smoke a single high dose (22% THC) of smoked cannabis cigarette
Primary Outcome Measures
NameTimeMethod
Mean speedChange in speed of driving between the time before smoking the cigarette and either 30 or 90 minutes after smoking the cigarette

Speed of driving the simulator

Secondary Outcome Measures
NameTimeMethod
Blood concentrations of THC and metabolitesChange from before smoking cigarette to various time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours

Blood will be taken to determine how much THC entered the blood

Heart rateChange from before smoking to a number of time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours

Vital signs

RespirationsChange from before smoking to a number of time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours

Vital signs

Verbal free recall testChange from pre-smoking levels to those observed 60 minutes after smoking

Test of memory: Participants will be asked to recall words that are read from a list

Standard deviation of lateral positionChange in measure from before smoking the cigarette to either 30 or 90 minutes after smoking

Driving measures

reaction timeChange in measure from before smoking the cigarette to either 30 or 90 minutes after smoking

Driving measures

TemperatureChange from before smoking to a number of time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours

Vital signs

Useful field of viewChange from pre-smoking levels to those observed 60 minutes after smoking

A computer test for visual processing speed, selective and divided attention

Oral fluid concentrations of THC and metabolitesChange from levels before smoking to 4 time points after smoking: 30 minutes, 90 minutes, 2 hours and 6 hours

Participants will provide oral fluid to determine how much THC is in the oral fluid

Systolic and Diastolic Blood pressureChange from before smoking to a number of time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours

Vital signs

Visual Analog ScalesChange from before smoking to a number of time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours

Tests designed to assess the degree of subjective effects of the drug. The questions will be scored on a scale from 0 to 100 and will consist of: 'I like this drug effect', 'this feels like cannabis', 'I feel this effect', 'I feel this high', 'I feel the good effects', 'I feel the bad effects', 'I feel the rush'

Trial Locations

Locations (1)

Center for Addiction and Mental Health

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath